{"id":"usual-doses-of-tigecycline","safety":{"commonSideEffects":[{"rate":"26","effect":"Nausea"},{"rate":"18","effect":"Vomiting"},{"rate":"12","effect":"Diarrhea"},{"rate":null,"effect":"Photosensitivity"},{"rate":null,"effect":"Increased intracranial pressure"},{"rate":null,"effect":"Tooth discoloration"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tigecycline is a broad-spectrum tetracycline antibiotic that binds to the bacterial 30S ribosomal subunit and blocks the attachment of aminoacyl-tRNA to the A site of the ribosome. This inhibits peptide chain elongation and results in bacteriostatic activity against a wide range of gram-positive, gram-negative, and anaerobic bacteria. It has enhanced activity compared to earlier tetracyclines due to structural modifications that reduce efflux-mediated resistance.","oneSentence":"Tigecycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing peptide elongation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:38:18.700Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Complicated skin and soft tissue infections"},{"name":"Complicated intra-abdominal infections"},{"name":"Community-acquired bacterial pneumonia"}]},"trialDetails":[{"nctId":"NCT07258225","phase":"PHASE4","title":"Clinical Effectiveness of a Once-daily Regimen of Tigecycline Compared to the Standard Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Air Force Specialized Hospital, Cairo, Egypt","startDate":"2024-04-01","conditions":"Multi Drug Resistant Infections","enrollment":86},{"nctId":"NCT05494957","phase":"PHASE4","title":"Clinical Study of New Intensive Treatment Regimen for Severe Nontuberculous Mycobacterial Pulmonary Disease","status":"UNKNOWN","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2022-08-05","conditions":"Nontuberculous Mycobacterial Lung Disease","enrollment":40},{"nctId":"NCT04876430","phase":"PHASE2, PHASE3","title":"Best Available Therapy With or Without Meropenem for Bloodstream Infections by Enterobacterales With High Level of Resistance to Carbapenems","status":"TERMINATED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2021-05-04","conditions":"Carbapenem-Resistant Enterobacteriaceae Infection, Bloodstream Infection","enrollment":13},{"nctId":"NCT01401023","phase":"NA","title":"Pharmacokinetics and Safety of Tigecycline in the Treatment of Clostridium Difficile Associated Diarrhea (CDAD)","status":"COMPLETED","sponsor":"Gary E. Stein, Pharm.D.","startDate":"2011-07","conditions":"Diarrhea, Clostridium Difficile","enrollment":10},{"nctId":"NCT00488488","phase":"","title":"A Pharmacovigilance Evaluation And Assessment Of The Prescribing Practice For Tygacil In Usual Health Care Setting","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-11","conditions":"Infection","enrollment":1028},{"nctId":"NCT00419991","phase":"PHASE4","title":"Open Label Non-comparative Clinical Trial of Tigecycline in Patients With Catheter Infection","status":"COMPLETED","sponsor":"CPL Associates","startDate":"2007-01","conditions":"Staphylococcal Infections","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Usual doses of tigecycline","genericName":"Usual doses of tigecycline","companyName":"Air Force Specialized Hospital, Cairo, Egypt","companyId":"air-force-specialized-hospital-cairo-egypt","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tigecycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing peptide elongation. Used for Complicated skin and soft tissue infections, Complicated intra-abdominal infections, Community-acquired bacterial pneumonia.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}